Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol
Introduction
The acoustic startle response (ASR) is a reflex contraction of the skeletal muscle that occurs in all mammals as a response to a sudden, intense acoustic stimulus. It is mediated by a simple pontine based neural circuit that has been well defined (Davis et al., 1982, Davis, 1997, Koch, 1999, Fendt et al., 2001). In humans, the eye-blink component of the startle response elicited by a strong, abrupt acoustic signal is measured by electromyographic (EMG) assessment of the orbicularis oculi facial muscle response (Graham, 1975). The ASR demonstrates several forms of behavioral plasticity, one of which is prepulse inhibition (PPI).
Prepulse inhibition of the startle response represents a normal attenuation of the startle reflex following the presentation of a weak prestimulus (prepulse) at brief intervals (i.e. between 30 and 500 ms) prior to the startle-eliciting stimulus (pulse). PPI has been observed in animals (Hoffman, 1997, Hoffman and Searle, 1968, Hoffman and Ison, 1992) and humans (Graham, 1975). The measured changes reflected in amplitude inhibition, latency of blink onset, and latency to peak amplitude reduction are indicators of inhibition of startle response. It is hypothesized that PPI reflects the functioning of a preattentive filtering system whereby the prepulse exerts an inhibitory influence until the processing of the prepulse is complete, thus protecting the organism against information overload and cognitive disruption (Braff et al., 1978).
In patients with schizophrenia, the ability to filter irrelevant exteroceptive or enteroceptive stimuli and discriminate important information from the environment is impaired, resulting in information overflow (Venables, 1964). Sensorimotor gating deficits may allow irrelevant thoughts and sensory stimuli into conscious awareness and contribute to the hallucinations, delusions and cognitive disintegration seen in schizophrenic patients (McGhie and Chapman, 1961).
Patients with schizophrenia display a fully normal initial startle response, but have impaired habituation of startle (Geyer and Braff, 1982, Geyer and Braff, 1987, Bolino et al., 1992, Parwani et al., 2000), and fail to display normal PPI. A number of studies have demonstrated such an impairment in PPI in subjects with schizophrenia (Braff et al., 1978, Braff et al., 1992, Braff et al., 1999, Braff et al., 2001, Braff and Geyer, 1990, Grillon et al., 1992, Bolino et al., 1994, Schall et al., 1996, Cadenhead et al., 2000, Weike et al., 2000, Parwani et al., 2000).
Deficient PPI has been proposed as a biologic marker of schizophrenia (Braff, 1993, Swerdlow and Geyer, 1998). However, the literature to date is inconclusive regarding the effect of treatment status on PPI. The studies demonstrating abnormal PPI have been conducted on patients who were on neuroleptics at the time of testing (Braff et al., 1978, Braff et al., 1992, Grillon et al., 1992, Bolino et al., 1994, Schall et al., 1996), indicating that treatment does not completely normalize PPI deficits. Several studies have reported results indicating a differential effect of medication status on PPI. Kumari et al. (1998) initially reported a trend level difference in PPI between subjects with schizophrenia treated with typical and atypical antipsychotics. A larger series from this group (Kumari et al., 2000) did not confirm this difference, but showed that only subjects on typical antipsychotics but not atypicals had less PPI than healthy controls. Weike et al. (2000) found PPI impairment only in five unmedicated subjects with schizophrenia compared to healthy controls, but no impairment in 20 medicated subjects with schizophrenia. Similarly, several recent between-group studies found that schizophrenic subjects treated with typical antipsychotics had reduced PPI compared to healthy controls (particularly at low to medium intervals between prepulse and pulse stimuli), whereas the atypical-treated subjects had normal PPI (Kumari et al., 1999, Kumari et al., 2002, Kumari and Sharma, 2002, Oranje et al., 2002b). Leumann et al. (2002) reported a similar finding, and additionally found a significant difference in PPI between subjects on typicals and atypicals.
On the other hand, several other studies report findings of no difference between subject groups differing in medication status. The study of Parwani et al. (2000) did not detect differences in PPI between unmedicated schizophrenic subjects and those on neuroleptics. Perry et al. (2002) found equivalent PPI deficits in acutely hospitalized subjects with schizophrenia whether they were on medication (including both atypicals and typicals) or unmedicated for the week prior to testing. In the first study using a within-subjects test–retest design, Mackeprang et al. (2002) found no increase in PPI when a group of first break schizophrenic patients were treated with either atypical or typical antipsychotic drugs. Finally, Duncan et al. (2003) used both a between-group and a within-subjects test–retest design, and reported that neither design detected significant differences in PPI between subjects on atypicals, typicals, or on no medication. Thus, the clinical literature leaves the issue of treatment status effect on PPI unresolved.
To date the effects of olanzapine on PPI in schizophrenia have not been specifically examined. In order to circumvent the possible confound of using treatment groups composed of subjects with inhomogenous medication status, the current study used a between-group design to examine acoustic startle and PPI in schizophrenic subjects stabilized on olanzapine or haloperidol compared to a group of acutely decompensated unmedicated schizophrenic subjects. Because habituation of the ASR has been reported to be impaired in schizophrenia, this measure was also compared. Latency of the ASR is shortened by the presence of a prepulse. This shortening, termed latency facilitation, provides evidence that the prepulse was detected, even in the face of the startle amplitude reduction seen with PPI. This measure was also studied in the subject groups in order to determine that the prepulse was detectable by the subject groups.
Section snippets
Subjects
IRB-approved informed consent for participation in the study was obtained from 46 male subjects with schizophrenia. The diagnosis of schizophrenia was established on the basis of chart reviews and the Structured Clinical Interview for DSM-IV, Axis-1 (SCID-1). Potential subjects were excluded if they had any other Axis I psychiatric disorder, active significant medical illness, history of any neurological condition, history of head trauma or loss of consciousness, presence of active substance
Clinical ratings
Between-group ANOVAs were significant for BPRS total score [F(2,37)=6.71, P=0.003], BPRS positive symptoms subscale [F(2,37)=7.96, P=0.001] and BPRS schizophrenia factor [F(2,37)=10.00, P=0.0003], reflecting in each case greater symptoms in the unmedicated group than in the olanzapine or haloperidol groups. The ANOVA on the BPRS negative symptom subscale was not significant [F(2,37)=1.57, P=0.22]. Data on clinical ratings and results of post hoc tests are presented in Table 2.
Startle amplitude and habituation
Differences in
Discussion
The main finding of this study was that PPI was comparable in schizophrenic subjects stabilized on olanzapine, stabilized on haloperidol, and acutely decompensated off medication.
Results from this study are in accord with earlier work from our lab (Parwani et al., 2000, Duncan et al., 2003) in which acutely ill, unmedicated subjects with schizophrenia did not differ in PPI from stable medicated subjects. The means for startle to pulse-alone stimuli as well as PPI were similar to values reported
Acknowledgements
This work was completed with the support of Eli Lilly and Company; the Atlanta Veterans Affairs Medical Center; Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences; the Department of Veterans Affairs New York Harbor Healthcare System; and New York University School of Medicine, Department of Psychiatry. The editorial assistance of Barbara Lewison and William Boshoven is gratefully acknowledged.
References (71)
- et al.
Startle reflex habituation in functional psychoses: a controlled study
Neuroscience Letters
(1992) - et al.
Sensorimotor gating and habituation evoked by electro-cutaneous stimulation in schizophrenia
Biological Psychiatry
(1994) - et al.
Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia
Schizophrenia Research
(2001) Neurochemical modulation of sensory-motor reactivity: acoustic and tactile startle reflexes
Neuroscience and Biobehavioral Reviews
(1980)- et al.
Clinical and sensorimotor gating effects of ketamine in normals
Neuropsychopharmacology
(2001) - et al.
Startle gating deficits occur across prepulse intensities in schizophrenic patients
Biological Psychiatry
(1992) - et al.
Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats
Pharmacology, Biochemistry and Behavior
(1995) The neurobiology of startle
Progress in Neurobiology
(1999)- et al.
Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics
Schizophrenia Research
(2002) - et al.
Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia
Biological Psychiatry
(2002)
Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients
Biological Psychiatry
Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat
European Journal of Pharmacology
‘Early’ and ‘late’ effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits
Neuropsychopharmacology
Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol
Biological Psychiatry
Impaired prepulse inhibition of acoustic startle in schizophrenia
Biological Psychiatry
Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics
Biological Psychiatry
Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients
Biological Psychiatry
Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats
Biological Psychiatry
Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
Journal of Pharmacology and Experimental Therapeutics
Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
Psychopharmacology
Prestimulus effects of human startle reflex in normals and schizophrenics
Psychophysiology
Sensorimotor gating and schizophrenia. Human and animal model studies
Archives of General Psychiatry
Gating and habituation of the startle reflex in schizophrenic patients
Archives of General Psychiatry
Information processing and attention dysfunctions in schizophrenia
Schizophrenia Bulletin
Symptom correlates of prepulse inhibition deficits in male schizophrenic patients
American Journal of Psychiatry
Wisconsin Card Sorting deficits and diminished sensorimotor gating in a discrete subgroup of schizophrenic patients
Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder
American Journal of Psychiatry
Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits
American Journal of Psychiatry
The neurophysiological basis of acoustic startle modulation: research on fear motivation and sensory gating
A primary acoustic startle circuit: lesion and stimulation studies
Journal of Neuroscience
Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulse in rats
Psychopharmacology
Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia
Psychopharmacology
Brain stem circuits mediating prepulse inhibition of the startle reflex
Psychopharmacology
The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating
Psychopharmacology
Habituation of the blink reflex in normals and schizophrenic patients
Psychophysiology
Cited by (45)
The effect of antipsychotic medications on acoustic startle latency in schizophrenia
2018, Schizophrenia ResearchCitation Excerpt :Startle latency has not been as extensively investigated as PPI, so the question of stability across medication conditions has not been as thoroughly researched. In two prior published papers from our group latency was not affected by medication status (Duncan et al., 2003a; Duncan et al., 2003b), nor was a significant effect reported by Swerdlow et al. (2006), although in the latter study the unmedicated group was quite small. Therefore, the purpose of this study was to examine the effects of antipsychotic medication status on startle latency and, by way of comparison, PPI.
Prepulse inhibition in patients with fragile X-associated tremor ataxia syndrome
2012, Neurobiology of AgingCitation Excerpt :A recent study found a relation between hippocampal volumes in FMR1 premutation carriers and frequent neuropsychiatric symptoms in FXTAS, especially anxiety, decreased attention, and restlessness (Adams et al., 2010) which may reflect impaired sensorimotor gating. PPI is an important marker of central nervous system (CNS) dysfunction in neuropsychiatric and neurodegenerative diseased and has been used in various medication outcome trials in the animal model and human trials, especially schizophrenia (Csomor et al., 2009; Duncan et al., 2003a, 2003b; Kumari et al., 2000; Weike et al., 2000). In an early review paper by Braff et al., the different studies with neurochemical compounds are evaluated, and the importance of comparable experimental parameters emphasized (Braff et al., 2001).
Startle response related genes
2011, Medical HypothesesHeritability of acoustic startle magnitude, prepulse inhibition, and startle latency in schizophrenia and control families
2010, Psychiatry ResearchCitation Excerpt :It has been suggested that PPI may be an endophenotype in schizophrenia based on several lines of evidence (Braff and Freedman, 2002; Gottesman and Gould, 2003). Many studies have found that SCZ subjects exhibit reduced PPI (Braff et al., 1978, 2001; Braff, 1992; Grillon et al., 1992; Dawson et al., 1993; Cadenhead et al., 2000; Parwani et al., 2000; Leumann et al., 2002; Ludewig et al., 2002; Duncan et al., 2003a; Kunugi et al., 2007). Some studies have shown these PPI deficits to be stable regardless of medication status (Braff et al., 1978; Braff, 1992; Grillon et al., 1992; Dawson et al., 1993; Cadenhead et al., 2000; Parwani et al., 2000; Hamm et al., 2001; Ludewig et al., 2002; Mackeprang et al., 2002; Perry et al., 2002; Duncan et al., 2003a,b).